IDO1 and lung cancer: If these pathways overlap in other immune cell types such as neutrophils or monocytes, then IDO knockdown, via shIDO-ST, may be directly responsible for upregulation of their ability to present antigen, and the overall effects of IDO knockdown may account for ICB synergy due to increased antigen presentation through multiple cell types in the LLC1 lung cancer model.